NCT04999449View on ClinicalTrials.gov

Nebulizer Delivery of Intranasal Scopolamine

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

May 7, 2025

Study Completion Date

May 7, 2025

Conditions

ScopolamineMotion Sickness

Interventions

DRUG

Scopolamine

Intranasal scopolamine at 0.2 mg or 0.4 mg

DRUG

Placebo

Intranasal saline placebo

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors

lead

Dartmouth-Hitchcock Medical Center

OTHER